LEVETIRACETAM DEXCEL 500

Country: Իսրայել

language: անգլերեն

source: Ministry of Health

active_ingredient:

LEVETIRACETAM

MAH:

DEXCEL PHARMA TECHNOLOGIES LTD

ATC_code:

N03AX14

pharmaceutical_form:

TABLETS

composition:

LEVETIRACETAM 500 MG

administration_route:

PER OS

prescription_type:

Required

manufactured_by:

DEXCEL LTD, ISRAEL

therapeutic_group:

LEVETIRACETAM

therapeutic_area:

LEVETIRACETAM

therapeutic_indication:

Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Dexcel is indicated as adjunctive therapy:• In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.• In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

authorization_date:

2018-03-31